Get the Stockscreener App
11.17
0.45%
0.05
Contineum Therapeutics Inc stock is traded at $11.17, with a volume of 63,546.
It is up +0.45% in the last 24 hours and up +7.51% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$11.12
Open:
$11.08
24h Volume:
63,546
Relative Volume:
0.39
Market Cap:
$325.97M
Revenue:
-
Net Income/Loss:
$-35.46M
P/E Ratio:
-26.48
EPS:
-0.4218
Net Cash Flow:
$-34.00M
1W Performance:
+3.81%
1M Performance:
+7.51%
6M Performance:
+153.29%
1Y Performance:
-20.95%
1-Day Range:
$10.86
$11.43
1-Week Range:
$10.42
$11.43
52-Week Range:
$3.35
$15.25
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
11.17 | 324.51M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
Will Contineum Therapeutics Inc. stock rally after Fed decisionsWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
Contineum Therapeutics, Inc. $CTNM Shares Purchased by Franklin Resources Inc. - MarketBeat
Critical Survey: BioMarin Pharmaceutical (NASDAQ:BMRN) & Contineum Therapeutics (NASDAQ:CTNM) - Defense World
Aug Volume: How risky is Contineum Therapeutics Inc. stock now2025 Geopolitical Influence & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
Support Test: Why Contineum Therapeutics Inc. stock attracts high net worth investorsMarket Performance Recap & Technical Analysis for Trade Confirmation - moha.gov.vn
CTNMContineum Therapeutics Latest Stock News & Market Updates - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Price Target Lowered to $14.00 at Robert W. Baird - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Given New $14.00 Price Target at Robert W. Baird - MarketBeat
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference - BioSpace
Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - Nasdaq
Contineum MS drug stumbles in mid-stage trial - Indian Pharma Post
CTNM: Analyst Baird Lowers Price Target to $14.00 but Maintains Outperform Rating | CTNM Stock News - GuruFocus
Royal Bank Of Canada Has Lowered Expectations for Contineum Therapeutics (NASDAQ:CTNM) Stock Price - Defense World
Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from RBC Capital - The Globe and Mail
RBC Capital Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - Nasdaq
Contineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis - marketscreener.com
Contineum’s MS drug falls short in Phase II trial - Yahoo Finance
Contineum’s PIPE-307 misses in midstage MS study - BioWorld MedTech
Contineum Therapeutics Inc trading resumes - MSN
Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value - Benzinga
Stifel maintains Buy rating on Contineum Therapeutics stock despite MS trial failure - Investing.com Canada
Contineum’s PIPE-307 Fails Phase II MS Trial, Focus Shifts To IPF Candidate - Citeline News & Insights
RBC Capital Lowers Price Target for Contineum Therapeutics (CTNM) | CTNM Stock News - GuruFocus
RBC Capital Lowers Price Target for Contineum Therapeutics (CTNM - GuruFocus
RBC Lowers Price Target on Contineum Therapeutics to $22 From $25, Keeps Outperform, Speculative Risk - MarketScreener
Contineum falls after missing main goals in multiple sclerosis trial - Seeking Alpha
Contineum stock down after MS drug fails in trial - The Pharma Letter
J&J, Contineum Fail ‘Risky’ Mid-Stage Multiple Sclerosis Trial - BioSpace
A look into Contineum Therapeutics Inc (CTNM)’s deeper side - Setenews
Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback - TipRanks
Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF - TipRanks
A brain biotech’s top drug fails against MS - BioPharma Dive
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - BioSpace
Stocks to Watch: Contineum, Gap Inc., Geospace Technologies - 富途牛牛
Optimistic Buy Rating for Contineum Therapeutics Amid Promising PIPE-791 Developments - TipRanks
Contineum’s multiple sclerosis drug fails to meet efficacy endpoints By Investing.com - Investing.com Nigeria
Contineum stock falls after multiple sclerosis drug fails in trial By Investing.com - Investing.com Australia
Contineum Therapeutics reports topline data from its phase 2 Pipe-307 Vista trial for the treatment of relapsing-remitting Multiple Sclerosis - marketscreener.com
Contineum stock falls after multiple sclerosis drug fails in trial - Investing.com
Contineum’s multiple sclerosis drug fails to meet efficacy endpoints - Investing.com
Contineum Therapeutics Reports Phase 2 Trial Results - TipRanks
Contineum Therapeutics, Inc. Reports Topline Data from its Phase 2 PIPE-307 Trial for the Treatment of Relapsing-Remitting Multiple SCLEROSIS - MarketScreener
[8-K] Contineum Therapeutics, Inc. Reports Material Event | CTNM SEC FilingForm 8-K - Stock Titan
Why Contineum Therapeutics Inc. stock could see breakout soon - newser.com
Real time social sentiment graph for Contineum Therapeutics Inc.2025 Price Momentum & Fast Exit Strategy with Risk Control - newser.com
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Morgan Stanley Raises Price Target on Contineum Therapeutics to $23 From $21, Keeps Overweight Rating - MarketScreener
How Contineum Therapeutics Inc. stock reacts to inflationary pressures2025 Risk Factors & Expert Curated Trade Setups - newser.com
Will Contineum Therapeutics Inc. stock benefit from automationQuarterly Portfolio Review & Proven Capital Preservation Methods - newser.com
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):